During regular trading hours, there were many stocks that continued to break up to the upside. These stocks are usually going up with news.If you are looking to day trade also check out my Top 2011 Stock Gainers , Stocks to Buy 2012.You can also check previous stocks to buy reports- Right Here today.Hot stocks Today Right Here.I also have technical analysis different stocks-Right Here. Market Technical analysis Right Here
Quick Look Market Closing Price:
At the close: Dow +1.34% to 12664. S&P +1.18% to 1330. Nasdaq +0.63% to 2836.
Treasurys: 30-year -0.24%. 10-yr -0.29%. 5-yr -0.1%.
Commodities: Crude +1.96% to $84.24. Gold +0.42% to $1626.15.
Currencies: Euro +0.5% vs. dollar. Yen -0.09%. Pound -0.31%.
After Hours News:
YPF S.A. (YPF)-Argentine oil producer nationalized in April, said Mexican billionaire Carlos Slim has taken an 8.4 percent stake as he boosts energy investments.After Hours: +8.8%
Microvision (MVIS) -3.7% AH after announcing a stock offering of undisclosed size. The company only says it intends to use the proceeds for "general corporate purposes." Microvision has been bleeding cash for much of its history, and only had $6.8M on its balance sheet as of March 30
Dyax (DYAX) -14% AH after declaring it will discontinue its Phase 2 trial for a drug meant to treat angiodema. Dyax says data from 72 patients taking part in the trials failed to produce a "statistically significant" difference in results for those taking its drug relative to those taking a placebo. Nonetheless, the company remains committed to broader angiodema drug development.
II-VI (IIVI) -7.6% AH after warning it expects FQ4 (ends June 30) revenue of $135M-$137M and EPS of $0.23-$0.25, below a consensus of $141.1M and $0.29. It's also guiding for FY13 revenue of $582M-$588M and EPS of $1.14-$1.21, below a consensus of $593M and $1.34. The provider of exotic high-tech materials and high-precision components says it's been hurt by soft demand and pricing for tellurium, and a slowdown for its Marlow thermoelectric cooler business.
Microvision (MVIS) -3.7% AH after announcing a stock offering of undisclosed size. The company only says it intends to use the proceeds for "general corporate purposes." Microvision has been bleeding cash for much of its history, and only had $6.8M on its balance sheet as of March 30
Dyax (DYAX) -14% AH after declaring it will discontinue its Phase 2 trial for a drug meant to treat angiodema. Dyax says data from 72 patients taking part in the trials failed to produce a "statistically significant" difference in results for those taking its drug relative to those taking a placebo. Nonetheless, the company remains committed to broader angiodema drug development.
II-VI (IIVI) -7.6% AH after warning it expects FQ4 (ends June 30) revenue of $135M-$137M and EPS of $0.23-$0.25, below a consensus of $141.1M and $0.29. It's also guiding for FY13 revenue of $582M-$588M and EPS of $1.14-$1.21, below a consensus of $593M and $1.34. The provider of exotic high-tech materials and high-precision components says it's been hurt by soft demand and pricing for tellurium, and a slowdown for its Marlow thermoelectric cooler business.
